To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients
NCT01023685
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Alzheimer Disease
Interventions
BIOLOGICAL:
CAD106
Sponsor
Novartis